Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07345494 · ClinicalTrials.gov registry record
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
A clinical trial of Hypoparathyroidism, sponsored by Ascendis Pharma A/S.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT07345494: Recruiting study of Hypoparathyroidism, sponsored by Ascendis Pharma A/S.
NCT07345494 is a study of Hypoparathyroidism that is actively recruiting participants, run by Ascendis Pharma A/S. The registered enrollment target is 50 participants, below the 195-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07345494, a study of Hypoparathyroidism, is actively recruiting participants, sponsored by Ascendis Pharma A/S.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this registry study is to collect both prospective and retrospective data in women exposed to palopegteriparatide during pregnancy to assess risk of pregnancy and maternal complications, and adverse effects on the developing fetus, neonate, and infant and to assess infant outcomes through at least the first year of life.
Conditions Studied
Interventions
- DRUG Palopegteriparatide
Study Locations (1)
West Virginia
- Ascendis Investigational Site - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-02-18 |
| Est. Completion | 2036-01 |
What NCT07345494 shows while recruiting
NCT07345494 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 195-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Hypoparathyroidism appearing as the primary indexed condition, and to 1 intervention - of which Palopegteriparatide is the first listed.
NCT07345494 reports a single indexed study location in West Virginia.
Frequently Asked Questions
What is clinical trial NCT07345494 about?
NCT07345494 is a clinical study titled "A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding". The purpose of this registry study is to collect both prospective and retrospective data in women exposed to palopegteriparatide during pregnancy to assess risk of pregnancy and maternal complications, and adverse effects on the developing fetus, neonate, and infant and to assess infant outcomes thr...
What is the current status of trial NCT07345494?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2026-02-18. Estimated completion is 2036-01.
What conditions does trial NCT07345494 study?
This clinical trial studies the following conditions: Hypoparathyroidism.
What interventions are being tested in trial NCT07345494?
The interventions under investigation include: Palopegteriparatide (DRUG).
Who is sponsoring clinical trial NCT07345494?
This trial is sponsored by Ascendis Pharma A/S, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07345494 being conducted?
This trial has 1 study location across West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoparathyroidism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07345494's enrollment target sits among peer trials
50 8th of 10 higher than 3 of 10 other Hypoparathyroidism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypoparathyroidism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hypoparathyroidism Natural History Study
RECRUITING
-
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
RECRUITING
-
Parathyroid Allotransplant for Treatment of Hypoparathyroidism
RECRUITING · Phase 1
-
A Registry for Participants With Chronic Hypoparathyroidism
ACTIVE NOT RECRUITING
-
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
ACTIVE NOT RECRUITING · Phase 2
-
Use of NPSP558 in the Treatment of Hypoparathyroidism
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI